Ken Griffin Ocuphire Pharma, Inc. Call Options Transaction History

Citadel Advisors LLC

9 transactions

Quarter	Operation	Price Per call	calls change	calls Held
Q3 2024 Nov 14, 2024	BUY	$1.19 - $2.07 $14,399 - $25,046	12,100 Added 605.0%	14,100 $18,000
Q2 2024 Aug 14, 2024	SELL	$1.51 - $2.23 $2,416 - $3,568	-1,600 Reduced 44.44%	2,000 $3,000
Q1 2024 May 15, 2024	SELL	$1.89 - $3.27 $14,364 - $24,852	-7,600 Reduced 67.86%	3,600 $7,000
Q4 2023 Feb 14, 2024	SELL	$2.59 - $3.64 $89,873 - $126,308	-34,700 Reduced 75.6%	11,200 $33,000
Q3 2023 Nov 14, 2023	BUY	$3.35 - $4.33 $97,150 - $125,570	29,000 Added 171.6%	45,900 $153,000
Q2 2023 Aug 14, 2023	BUY	$3.63 - $6.38 $14,157 - $24,882	3,900 Added 30.0%	16,900 $73,000
Q1 2023 May 15, 2023	BUY	$3.01 - $3.85 $31,604 - $40,425	10,500 Added 420.0%	13,000 $48,000
Q4 2022 Feb 14, 2023	SELL	$2.04 - $3.53 $45,900 - $79,425	-22,500 Reduced 90.0%	2,500 $8,000
Q3 2022 Nov 14, 2022	SELL	$1.82 - $2.79 $4,732 - $7,254	-2,600 Reduced 9.42%	25,000 $50,000

2.58M

14.1K

800

Ticker OCUP
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 20,579,800
Market Cap $20.2M
Description
Ocuphire Pharma, Inc., a clinical-stage ophthalmic biopharmaceutical company, focuses on developing and commercializing therapies for the treatment of refractive and retinal eye disorders. Its lead product candidate is Nyxol eye drops, a once-daily preservative-free eye drop formulation of phentolamine mesylate, which is in Phase III clinical tr...

Get notified when there are updates to the investment portfolio of Citadel Advisors LLC, based on Form 13F filings with the SEC.

Stay updated on Citadel Advisors LLC and Ken Griffin with notifications on news.